Benha University

bu.edu.eg

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

331

Active

55

Phase 3

29

Total enrollment

49,166

Pipeline matrix

Showing 27 of 27 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Bupivacaine5
Dexmedetomidine12
Melatonin2
Bupivacaine and Dexmedetomidine1
TNF-α Inhibitor1
Fentanyl4
Oral intake of sildosin1
Hyaluronidase2
Dexamethasone3
Botulinum toxin type A3
Sedation with Midazolam, Fentanyl, and Propofol1
Dexamethasone and dexmedetomidine1
Vitamin B Complex1
vitamin C1
Haloperidol1
Hyaluronic acid1
Midazolam plus ultrasound-guided spinal anesthesia1
Palmitoylethanolamide1
Ibuprofen1
Platelet-Rich Plasma1
Intravesical Botulinum Toxin1
Calcium and Vitamin D Supplementation1
frusemide1
Pregabalin1
Bacillus clausii1
Caudal Bupivacaine1
Caudal Dexmedetomidine1

Next readouts

  • 2025-07
  • 2025-09-01
  • 2025-11
  • 2025-12-15
  • 2026-01
  • 2026-03
  • 2026-04-10
  • 2026-04-15
  • 2026-05-01
  • 2026-05-01

Top conditions

  • Infertility9
  • Eyelid Diseases8
  • Pain, Postoperative8
  • COVID-197
  • Cesarean Section Complications7
  • Postoperative Pain5
  • Retinal Detachment5
  • Endometriosis4

Frequently asked questions about Benha University

How many clinical trials does Benha University have on ClinicalTrials.gov?
Benha University is listed as the lead sponsor on 331 clinical trials in ClinicalTrials.gov, 55 of which are currently active (recruiting, enrolling, or ongoing).
How many of Benha University's trials are in Phase 3?
29 of Benha University's trials are in Phase 3, spread across 27 active drug programs.
What therapeutic areas does Benha University focus on?
Benha University's most-studied conditions on ClinicalTrials.gov are Infertility, Eyelid Diseases, Pain, Postoperative, COVID-19, Cesarean Section Complications.
When are Benha University's next clinical trial readouts?
Benha University has 10 upcoming primary-completion readouts tracked here; the soonest is “Decongestion Guided By VExUS Score Or Lung Ultrasound For Renal Recovery In Patients With Cardiorenal Syndrome Type -1”, expected around 2025-07.